• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

mGM-CSF/βhCG融合蛋白的制备及其致敏树突状细胞疫苗抗小鼠RM-1前列腺癌的作用

曹荣月, 常娜, 李曼曼, 王云康, 吴迪, 时宝莹, 袁玉婷, 龙军

曹荣月, 常娜, 李曼曼, 王云康, 吴迪, 时宝莹, 袁玉婷, 龙军. mGM-CSF/βhCG融合蛋白的制备及其致敏树突状细胞疫苗抗小鼠RM-1前列腺癌的作用[J]. 中国药科大学学报, 2015, 46(1): 111-116. DOI: 10.11665/j.issn.1000-5048.20150117
引用本文: 曹荣月, 常娜, 李曼曼, 王云康, 吴迪, 时宝莹, 袁玉婷, 龙军. mGM-CSF/βhCG融合蛋白的制备及其致敏树突状细胞疫苗抗小鼠RM-1前列腺癌的作用[J]. 中国药科大学学报, 2015, 46(1): 111-116. DOI: 10.11665/j.issn.1000-5048.20150117
shu
CAO Rongyue, CHANG Na, LI Manman, WANG Yunkang, WU Di, SHI Baoying, YUAN Yuting, LONG Jun. Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice[J]. Journal of China Pharmaceutical University, 2015, 46(1): 111-116. DOI: 10.11665/j.issn.1000-5048.20150117
Citation: CAO Rongyue, CHANG Na, LI Manman, WANG Yunkang, WU Di, SHI Baoying, YUAN Yuting, LONG Jun. Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice[J]. Journal of China Pharmaceutical University, 2015, 46(1): 111-116. DOI: 10.11665/j.issn.1000-5048.20150117
shu

mGM-CSF/βhCG融合蛋白的制备及其致敏树突状细胞疫苗抗小鼠RM-1前列腺癌的作用

  • 1.

    中国药科大学微基因药学实验室

  • 2.

    南京中医药大学食品药品毒理学教研室

基金项目: 国家自然科学基金资助项目(No.81172973,81373232)；江苏高校优势学科建设工程资助项目；国家大学生创新创业训练计划资助项目(No.J1030830)

Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice

摘要

    摘要
  • 摘要: 利用分子生物学方法设计并构建含有βhCG基因和mGM-CSF基因的表达载体pET-28a-mGM-CSF-X10-βhCGCTP37质粒。乳糖诱导表达该融合蛋白，通过硫酸铵分级沉淀和阴离子交换柱DEAE-cellulose进行纯化，并以此融合蛋白致敏从C57BL/6J小鼠体内提取的树突状细胞(DC)从而获得DC疫苗。将DC疫苗回输至接种前列腺癌RM-1的C57BL/6J小鼠体内，分组检测。结果显示，DC组和DC与紫杉醇(Pac)联用(DP)组与Pac组相比抗肿瘤效果具有极显著性差异(P<；0.01)；且DP组的抗肿瘤效果优于DC组。可见构建的新型DC疫苗可抑制前列腺癌的生长，且与紫杉醇联合使用具有协同抗肿瘤作用。
    Abstract: An expression vector pET-28a-mGM-CSF-X10-βhCGCTP37 plasmid containing the βhCG and mGM-CSF gene was designed and constructed. The fusion protein was induced by lactose and purified by ammonium sulfate precipitation and DEAE-cellulose anion exchange column. Then dendritic cells(DC)in C57BL/6J mice were extracted and sensitized by the fusion protein to obtain DC vaccine. The DC vaccine was inoculated to C57BL of / 6J mice with prostate cancer RM-1. The results indicated that the anti-tumor effects of DC group and DC combined with paclitaxel(DP)group were superior to that of paclitaxel(Pac)group(P< 0. 01), and the anti-tumor effect of DP group was better than that of DC group. Thus, the constructed DC vaccine can inhibit the growth of prostate cancer, and have synergistic anti-tumor when used with paclitaxel.
    • HTML全文
    • 参考文献(13)
  • [1] Small EJ,Fratesi P,Reese DM, et al.Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells[J].J Clin Oncol,2000,18(23):3894-3903.
    [2] Abdulla A,Kappoor A.Emerging novel therapies in the treatment of castrate-resistant prostate cancer[J].Can Urol Assoc J,2011,5(2):120-133.
    [3] Sims RB.Development of sipuleucel-T:autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer[J].Vaccine,2012,30(29):4394-4397.
    [4] Iles RK,Delves PJ,Butler SA.Does hCG or hCGβ play a role in cancer cell biology[J].Mol Cell Endocrinol,2010,329(1/2):62-70.
    [5] Cole LA.hCG,five independent molecules[J].Clin Chim Acta,2012,413(1/2):48-65.
    [6] Cole LA.Hyperglycosylated hCG,a review[J].Placenta,2010,31(8):653-664.
    [7] Cole LA,Butler S.Hyperglycosylated hCG,hCGβ and hyperglycosylated hCGβ:interchangeable cancer promoters[J].Mol Cell Endocrinol,2012, 349(2):232-238.
    [8] Cheng YC,Valero V,Davis ML, et al.Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients[J].Br J Cancer,2010,103(9):1331-1334.
    [9] Somani J,Lonial S,Rosenthal H, et al.A randomized,placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant:effect on cellular and humoral immune responses[J].Vaccine,2002,21(3/4):221-230.
    [10] Garcia F,Climent N,Assoumou L, et al.A therapeutic dendritic cell-based vaccine for HIV-1 infection[J].J Infect Dis,2011, 203(4):473-478.
    [11] Skalova K,Mollova K,Michalek J.Human myeloid dendritic cells for cancer therapy:does maturation matter[J]?Vaccine,2010,28(32):5153-5160.
    [12] Yin W,He Q,Hu Z, et al.A novel therapeutic vaccine of GM-CSF/TNFα surface-modified RM-1 cells against the orthotopic prostatic cancer[J].Vaccine,2010,28(31):4937-4944.
    [13] Inaba K,Inaba M,Romani N, et al.Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor[J].J Exp Med,1992, 176(6):1693-1702.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1434
  • HTML全文浏览量:  0
  • PDF下载量:  2211
  • 被引次数: 0
出版历程
  • 刊出日期:  2015-02-24

目录

摘要
HTML全文
    参考文献(13)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：400356

    x 关闭 永久关闭